Secondary bacterial infections in influenza virus infection pathogenesis

Current Topics in Microbiology and Immunology

Volumn 385, Issue , 2014, Pages 327-356

  Smith, Amber M ^a   McCullers, Jonathan A ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; INFLUENZA VACCINE; PERTUSSIS VACCINE; SIALIDASE INHIBITOR; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT;

ACUTE OTITIS MEDIA; ANTIMICROBIAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL LOAD; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DISEASE MODEL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLUENZA; KINETICS; MIDDLE EAR; MIXED INFECTION; MUCOSAL IMMUNITY; NASOPHARYNX; NONHUMAN; ORGANISMAL INTERACTION; PATHOGENESIS; PATHOPHYSIOLOGY; PNEUMOCOCCAL INFECTION; PNEUMONIA; SECONDARY INFECTION; SIGNAL TRANSDUCTION; VACCINATION; VIRAL CLEARANCE; VIRUS TRANSMISSION; ANIMAL; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PHENOMENA AND FUNCTIONS; COINFECTION; COMPLICATION; DRUG EFFECTS; INFLUENZA, HUMAN; MICROBIOLOGY; ORTHOMYXOVIRUS; PATHOGENICITY; PHYSIOLOGY; VIROLOGY;

ANIMALIA; BACTERIA (MICROORGANISMS); ORTHOMYXOVIRIDAE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; COINFECTION; HUMANS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE;

EID: 84921653338     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2014_394     Document Type: Article

References (176)

1. Abramson JS, Giebink GS, Mills EL, Quie PG (1981) Polymorphonuclear leukocyte dysfunction during influenza virus infection in chinchillas. J Infect Dis 143:836–845. doi:10.1093/infdis/ 143.6.836
2. Abramson JS, Giebink GS, Quie PG (1982) Influenza A virus-induced polymorphonuclear leukocyte dysfunction in the pathogenesis of experimental pneumococcal otitis media. Infect Immun 36:289–296
3. Abt MC, Osborne LC, Monticelli LA et al (2012) Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 37:158–170. doi:10.1016/j.immuni.2012.04. 011
4. Alymova IV, Green AM, van de Velde N et al (2011) Immunopathogenic and antibacterial effects of H3N2 influenza A virus PB1-F2 map to amino acid residues 62, 75, 79, and 82. J Virol 85:12324–12333. doi:10.1128/JVI.05872-11
5. Ansaldi F, de Florentiis D, Parodi V et al (2012) Bacterial carriage and respiratory tract infections in subjects[or = 60 years during an influenza season: implications for the epidemiology of community acquired pneumonia and influenza vaccine effectiveness. J Prev Med Hyg 53:94–97
6. Ayala VI, Teijaro JR, Farber DL et al (2011) Bordetella pertussis infection exacerbates influenza virus infection through pertussis toxin-mediated suppression of innate immunity. PLoS ONE 6:e19016. doi:10.1371/journal.pone.0019016
7. Baccam P, Beauchemin C, Macken CA et al (2006) Kinetics of influenza a virus infection in humans. J Virol 80:7590–7599. doi:10.1128/JVI.01623-05
8. Barclay AN, Wright GJ, Brooke G, Brown MH (2002) CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 23:285–290. doi:10.1016/S1471- 4906(02)02223-8
9. Beauchemin CA, Handel A (2011) A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead. BMC Public Health 11:S7. doi:10.1186/1471-2458-11-S1-S7
10. Beighton D, Whiley RA (1990) Sialidase activity of the ‘‘Streptococcus milleri group’’ and other viridans group Streptococci. J Clin Microbiol 28:1431–1433
11. Berendt RF, Long GG, Walker JS (1975) Influenza alone and in sequence with pneumonia due to Streptococcus pneumoniae in the squirrel monkey. J Infect Dis 132:689–693. doi:10.1093/ infdis/132.6.689
12. Bosch AATM, Biesbroek G, Trzcinski K et al (2013) Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog 9:e1003057. doi:10.1371/journal.ppat.1003057
13. Bradley JS, Byington CL, Shah SS et al (2011) The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America. Clin Infect Dis 53:e25–e76. doi:10.1093/cid/cir531
14. Brundage JF, Shanks GD (2007) What really happened during the 1918 influenza pandemic? The importance of bacterial secondary infections. J Infect Dis 196:1717–1718. doi:10.1086/522355
15. Camara M, Mitchell TJ, Andrew PW, Boulnois GJ (1991) Streptococcus pneumoniae produces at least two distinct enzymes with neuraminidase activity: cloning and expression of a second neuraminidase gene in Escherichia coli. Infect Immun 59:2856–2858
16. Canini L, Carrat F (2010) Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. J Virol 85:2764–2770. doi:10.1128/JVI.01318-10
17. Centers for Disease Control Deaths and Mortality
18. Centers for Disease Control Estimated Burden of Acute Otits Externa
19. Chanturiya AN, Basanez G, Schubert U et al (2004) PB1-F2, an influenza A virus-encoded proapoptotic mitochondrial protein, creates variably sized pores in planar lipid membranes. J Virol 78:6304–6312. doi:10.1128/JVI.78.12.6304-6312.2004
20. Chaussee MS, Sandbulte HR, Schuneman MJ et al (2011) Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections. Vaccine 29:3773–3781. doi:10.1016/j.vaccine.2011.03.031
21. Chen W, Calvo PA, Malide D et al (2001) A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 7:1306–1312. doi:10.1038/nm1201-1306
22. Colamussi ML, White MR, Crouch E, Hartshorn KL (1999) Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria. Blood 93:2395–2403
23. Conenello GM, Tisoncik JR, Rosenzweig E et al (2011) A single N66S mutation in the PB1-F2 protein of influenza A virus increases virulence by inhibiting the early interferon response in vivo. J Virol 85:652–662. doi:10.1128/JVI.01987-10
24. Conenello GM, Zamarin D, Perrone LA et al (2007) A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog 3:e141. doi:10.1371/journal.ppat.0030141
25. Cundell DR, Gerard NP, Gerard C et al (1995) Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 377:435–438. doi:10.1038/377435a0
26. Danishuddin M, Khan SN, Khan AU (2010) Molecular interactions between mitochondrial membrane proteins and the C-terminal domain of PB1-F2: an in silico approach. J Mol Model 16:535–541. doi:10.1007/s00894-009-0555-5.
27. Diavatopoulos DA, Short KR, Price JT et al (2010a) Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. FASEB J 24:1789–1798. doi:10.1096/fj.09-146779.
28. Diavatopoulos DA, Short KR, Price JT et al (2010b) Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. FASEB J 24:1789–1798. doi:10.1096/fj.09-146779.
29. Didierlaurent A, Goulding J, Patel S et al (2008) Sustained desensitization to bacterial toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 205:323–329. doi:10.1084/jem.20070891.
30. Dockrell DH, Marriott HM, Prince LR et al (2003) Alveolar macrophage apoptosis contributes to pneumococcal clearance in a resolving model of pulmonary infection. J Immunol (Baltimore Md 1950) 171:5380–5388.
31. Domínguez-Cherit G (2009) Critically ill patients with 2009. influenza A(H1N1) in Mexico. JAMA 302:1880. doi:10.1001/jama.2009.1536.
32. Duval X, van der Werf S, Blanchon T et al (2010) Efficacy of Oseltamivir-Zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebocontrolled trial. PLoS Med 7:e1000362. doi:10.1371/journal.pmed.1000362.
33. Engelich G, White M, Hartshorn KL (2001) Neutrophil survival is markedly reduced by incubation with influenza virus and Streptococcus pneumoniae: role of respiratory burst. J Leukoc Biol 69:50–56.
34. Fainstein V, Musher DM, Cate TR (1980) Bacterial adherence to pharyngeal cells during viral infection. J Infect Dis 141:172–176. doi:10.1093/infdis/141.2.172.
35. File TM Jr, Marrie TJ (2010) Burden of community-acquired pneumonia in North American adults. Postgrad Med 122:130–141. doi:10.3810/pgm.2010.03.2130.
36. Fillion I, Ouellet N, Simard M et al (2001) Role of chemokines and formyl peptides in pneumococcal pneumonia-induced monocyte/macrophage recruitment. J Immunol (Baltimore Md 1950) 166:7353–7361.
37. Francis T, de Torregrosa MV (1945) Combined infection of mice with H. influenzae and influenza virus by the intranasal route. J Infect Dis 76:70–77. doi:10.2307/30085688.
38. García-Rodríguez JA, Fresnadillo Martínez MJ (2002) Dynamics of nasopharyngeal colonization by potential respiratory pathogens. J Antimicrob Chemother 50. Suppl S2:59–73.
39. Ghoneim HE, McCullers JA (2013) Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice. J Infect Dis. doi:10.1093/infdis/jit653.
40. Ghoneim HE, Thomas PG, McCullers JA (2013) Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol 191:1250–1259. doi:10.4049/jimmunol.1300014.
41. Gibbs JS, Malide D, Hornung F et al (2003) The influenza A virus PB1-F2. protein targets the inner mitochondrial membrane via a predicted basic amphipathic helix that disrupts mitochondrial function. J Virol 77:7214–7224. doi:10.1128/JVI.77.13.7214-7224.2003.
42. Giebink G, Ripley M, Wright P (1987) Eustachian tube histopathology during experimental influenza A virus infection in the chinchilla. Ann Otol Rhinol Laryngol 96:199–206.
43. Giles C, Shuttleworth EM (1957) Postmortem findings in 46. influenza deaths. Lancet 273:1224–1225.
44. le Goffic R, Bouguyon E, Chevalier C et al (2010) Influenza A virus protein PB1-F2. exacerbates IFN-expression of human respiratory epithelial cells. J Immunol 185:4812–4823. doi:10.4049/jimmunol.0903952.
45. Goulding J, Godlee A, Vekaria S et al (2011) Lowering the threshold of lung innate immune cell activation alters susceptibility to secondary bacterial superinfection. J Infect Dis 204:1086–1094. doi:10.1093/infdis/jir467.
46. Gwaltney JM, Sande MA, Austrian R, Hendley JO (1975) Spread of Streptococcus pneumoniae in families. II. Relation of transfer of S. pneumoniae to incidence of colds and serum antibody. J Infect Dis 132:62–68. doi:10.1093/infdis/132.1.62.
47. Hai R, Schmolke M, Varga ZT et al (2010) PB1-F2. expression by the 2009. pandemic H1N1. influenza virus has minimal impact on virulence in animal models. J Virol 84:4442–4450. doi:10.1128/JVI.02717-09.
48. Hajek DM, Yuan Z, Quartey MK, Giebink GS (1999) Otitis media: the chinchilla model. In: Zak O, Sande MA (eds) Handbook of animal models of infection: experimental models in antimicrobial chemotherapy Academic, San Diego, CA, pp 389–401.
49. Hale BG, Randall RE, Ortin J, Jackson D (2008) The multifunctional NS1. protein of influenza A viruses. J Gen Virol 89:2359–2376. doi:10.1099/vir.0.2008/004606-0.
50. Handel A, Longini IM, Antia R (2010) Towards a quantitative understanding of the within-host dynamics of influenza A infections. J R Soc Interface 7:35–47. doi:10.1098/rsif.2009.0067.
51. Hayden FG (2006) Antiviral resistance in influenza viruses—implications for management and pandemic response. N Engl J Med 354:785–788. doi:10.1056/NEJMp068030.
52. Hayden FG (2013) Newer influenza antivirals, biotherapeutics and combinations: novel influenza antivirals and therapeutics. Influenza Other Respir Viruses 7:63–75. doi:10.1111/irv.12045.
53. Heikkinen T (2000) The role of respiratory viruses in otitis media. Vaccine 19:S51–S55. doi:10.1016/S0264-410X(00)00278-4.
54. Herzog H, Staub H, Richterich R (1959) Gas-analytical studies in severe pneumonia; observations during the 1957. influenza epidemic. Lancet 1:593–597.
55. Hirano T, Kurono Y, Ichimiya I et al (1999) Effects of influenza A virus on lectin-binding patterns in murine nasopharyngeal mucosa and on bacterial colonization. Otolaryngol Head Neck Surg 121:616–621. doi:10.1016/S0194-5998(99)70068-9.
56. Homer KA, Kelley S, Hawkes J et al (1996) Metabolism of glycoprotein-derived sialic acid and N-acetylglucosamine by Streptococcus oralis. Microbiol Read Engl 142(Pt 5):1221–1230.
57. Huber VC, Peltola V, Iverson AR, McCullers JA (2010) Contribution of Vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications. J Virol 84:4105–4108. doi:10.1128/JVI.02621-09.
58. Hughes MT, Matrosovich M, Rodgers ME et al (2000) Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice. J Virol 74:5206–5212. doi:10.1128/JVI.74.11.5206-5212.2000.
59. Hussell T, Cavanagh MM (2009) The innate immune rheostat: influence on lung inflammatory disease and secondary bacterial pneumonia. Biochem Soc Trans 37:811. doi:10.1042/BST0370811.
60. Ichinohe T, Pang IK, Kumamoto Y et al (2011) Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Nat Acad Sci U.S.A 108:5354–5359. doi:10. 1073/pnas.1019378108.
61. Iverson AR, Boyd KL, McAuley JL et al (2011) Influenza virus primes mice for pneumonia from Staphylococcus aureus. J Infect Dis 203:880–888. doi:10.1093/infdis/jiq113.
62. Jain S, Kamimoto L, Bramley AM et al (2009) Hospitalized patients with 2009. H1N1. influenza in the United States, April–June 2009. N Engl J Med 361:1935–1944. doi:10.1056/NEJMoa0906695.
63. Jamieson AM, Yu S, Annicelli CH, Medzhitov R (2010) Influenza virus-induced glucocorticoids compromise innate host defense against a secondary bacterial infection. Cell Host Microbe 7:103–114. doi:10.1016/j.chom.2010.01.010.
64. Jiang-Shieh Y-F, Chien H-F, Chang C-Y et al (2010) Distribution and expression of CD200. in the rat respiratory system under normal and endotoxin-induced pathological conditions. J Anat 216:407–416. doi:10.1111/j.1469-7580.2009.01190.x
65. Jonsson S, Musher DM, Chapman A et al (1985) Phagocytosis and killing of common bacterial pathogens of the lung by human alveolar macrophages. J Infect Dis 152:4–13. doi:10.1093/infdis/152.1.4.
66. Joyce EA, Popper SJ, Falkow S (2009) Streptococcus pneumoniae nasopharyngeal colonization induces type I interferons and interferon-induced gene expression. BMC Genomics 10:404. doi:10.1186/1471-2164-10-404.
67. Kadioglu A, Weiser JN, Paton JC, Andrew PW (2008) The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 6:288–301. doi:10.1038/nrmicro1871.
68. Karlström Å, Boyd KL, English BK, McCullers JA (2009) Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 199:311–319. doi:10.1086/596051.
69. Karlstrom A, Heston SM, Boyd KL et al (2011) Toll-like receptor 2. mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J Infect Dis 204:1358–1366. doi:10.1093/infdis/jir522.
70. Knapp S, Leemans JC, Florquin S et al (2003) Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 167:171–179. doi:10.1164/rccm.200207-698OC
71. Kobayashi SD, Braughton KR, Palazzolo-Ballance AM et al (2010) Rapid neutrophil destruction following phagocytosis of Staphylococcus aureus. J. Innate Immun 2:560–575. doi:10.1159/ 000317134.
72. Kobayashi SD, Braughton KR, Whitney AR et al (2003) Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. Proc Nat Acad Sci U.S.A 100:10948–10953. doi:10.1073/pnas.1833375100.
73. Koppe U, Suttorp N, Opitz B (2012) Recognition of Streptococcus pneumoniae by the innate immune system: Innate immune recognition of Streptococcus pneumoniae. Cell Microbiol 14:460–466. doi:10.1111/j.1462-5822.2011.01746.x
74. Kudva A, Scheller EV, Robinson KM et al (2011) Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol (Baltimore Md 1950) 186:1666–1674. doi:10.4049/jimmunol.1002194.
75. Kumar A (2009) Critically ill patients with 2009. influenza A(H1N1) infection in Canada. JAMA 302:1872. doi:10.1001/jama.2009.1496.
76. Kuri T, Smed Sörensen A, Thomas S et al (2013) Influenza A virus-mediated priming enhances cytokine secretion by human dendritic cells infected with Streptococcus pneumoniae: Influenza virus and pneumococcal co-infection of human DCs. Cell Microbiol 15:1385–1400. doi:10.1111/cmi.12122.
77. Laennec RTH (1923) Translation of selected passages from De l’auscultation mediate. Bale & Danielsson, London
78. Lee LN, Dias P, Han D et al (2010) A mouse model of lethal synergism between influenza virus and haemophilus influenzae. Am J Pathol 176:800–811. doi:10.2353/ajpath.2010.090596.
79. Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10:S122–S129. doi:10.1038/nm1145.
80. Li R, Lim A, Phoon MC et al (2010) Attenuated bordetella pertussis protects against highly pathogenic influenza a viruses by dampening the cytokine storm. J Virol 84:7105–7113. doi:10.1128/JVI.02542-09.
81. Li W, Moltedo B, Moran TM (2012) Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of γd T cells. J Virol 86:12304–12312. doi:10.1128/JVI.01269-12.
82. Licciardi PV, Toh ZQ, Dunne E et al (2012) Protecting against ppneumococcal disease: critical interactions between probiotics and the airway microbiome. PLoS Pathog 8:e1002652. doi:10.1371/journal.ppat.1002652.
83. Liu C, Air GM (1993) Selection and characterization of a neuraminidase-minus mutant of influenza virus and its rescue by cloned neuraminidase genes. Virology 194:403–407. doi:10.1006/viro.1993.1276.
84. Liu X, He Y, Xiao K et al (2013) Effect of linezolid on clinical severity and pulmonary cytokines in a murine model of influenza A and Staphylococcus aureus coinfection. PLoS ONE 8:e57483. doi:10.1371/journal.pone.0057483.
85. Louie J, Jean C, Chen TH et al (2009) Bacterial coinfections in lung tissue specimens from fatal cases of 2009. pandemic influenza A (H1N1)—United States, May-August 2009. Morb Mortal Wkly Rep 58:1071–1074.
86. Louria DB, Blumenfeld HL, Ellis JT et al (1959) Studies on influenza in the pandemic of 1957- 1958. II. Pulmonary Complications Of Influenza. J Clin Invest 38:213–265. doi:10.1172/JCI103791.
87. Loving CL, Brockmeier SL, Vincent AL et al (2010) Influenza virus coinfection with Bordetella bronchiseptica enhances bacterial colonization and host responses exacerbating pulmonary lesions. Microb Pathog 49:237–245. doi:10.1016/j.micpath.2010.06.004.
88. Ludewick HP, Aerts L, Hamelin M-E, Boivin G (2011) Long-term impairment of Streptococcus pneumoniae lung clearance is observed after initial infection with influenza A virus but not human metapneumovirus in mice. J Gen Virol 92:1662–1665. doi:10.1099/vir.0.030825-0.
89. Marks LR, Davidson BA, Knight PR, Hakansson AP (2013) Interkingdom signaling induces streptococcus pneumoniae biofilm dispersion and transition from asymptomatic colonization to disease. mBio 4:e00438–13. doi:10.1128/mBio.00438-13.
90. McAuley JL, Chipuk JE, Boyd KL et al (2010a) PB1-F2. proteins from H5N1. and 20th century pandemic influenza viruses cause immunopathology. PLoS Pathog 6:e1001014. doi:10.1371/journal.ppat.1001014.
91. McAuley JL, Hornung F, Boyd KL et al (2007) Expression of the 1918. influenza A virus PB1-F2. enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2:240–249. doi:10.1016/j.chom.2007.09.001.
92. McAuley JL, Zhang K, McCullers JA (2010b) The effects of influenza A virus PB1-F2. protein on polymerase activity are strain specific and do not impact pathogenesis. J Virol 84:558–564. doi:10.1128/JVI.01785-09.
93. McCullers JA (2001) Molecular pathogenesis of pneumococcal pneumonia. Front Biosci 6:d877. doi:10.2741/McCullers
94. McCullers JA (2005) Antiviral therapy of influenza. Expert Opin Investig Drugs 14:305–312. doi:10.1517/13543784.14.3.305.
95. McCullers JA (2011) Preventing and treating secondary bacterial infections with antiviral agents. Antivir Ther 16:123–135. doi:10.3851/IMP1730.
96. McCullers JA (2014) The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol 12:252–262. doi:10.1038/nrmicro3231.
97. McCullers JA (2004) Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 190:519–526. doi:10.1086/421525.
98. McCullers JA, Bartmess KC (2003) Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 187:1000–1009. doi:10.1086/368163.
99. McCullers JA, English BK (2008) Improving therapeutic strategies for secondary bacterial pneumonia following influenza. Future Microbiol 3:397–404. doi:10.2217/17460913.3.4.397.
100. McCullers JA, Karlström Å, Iverson AR et al (2007) Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog 3:e28. doi:10.1371/journal.ppat.0030028.
101. McCullers JA, McAuley JL, Browall S et al (2010) Influenza enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in ferrets. J Infect Dis 202:1287–1295. doi:10.1086/656333.
102. McCullers JA, Rehg JE (2002) Lethal synergism between influenza virus and streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 186:341–350. doi:10.1086/341462.
103. McHugh KJ, Mandalapu S, Kolls JK et al (2013) A novel outbred mouse model of 2009. pandemic influenza and bacterial co-infection severity. PLoS ONE 8:e82865. doi:10.1371/journal.pone.0082865.
104. McNamee LA, Harmsen AG (2006) Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect Immun 74:6707–6721. doi:10.1128/IAI.00789-06.
105. Metzger DW, Sun K (2013) Immune dysfunction and bacterial coinfections following influenza. J Immunol 191:2047–2052. doi:10.4049/jimmunol.1301152.
106. Miao H, Hollenbaugh JA, Zand MS et al (2010) Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol 84:6687–6698. doi:10.1128/JVI.00266-10.
107. Miao H, Xia X, Perelson AS, Wu H (2011) On identifiability of nonlinear ODE models and applications in viral dynamics. SIAM Rev 53:3–39. doi:10.1137/090757009.
108. Miller ML, Gao G, Pestina T et al (2007) Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves platelet-activating factor receptor. J Infect Dis 195:581–584. doi:10.1086/510626.
109. Mina MJ, Klugman KP, McCullers JA (2013) Liveattenuated influenza vaccine, but not pneumococcal conjugate vaccine, protects against increased density and duration of pneumococcal carriage after influenza infection in pneumococcal colonized mice. J Infect Dis 208:1281–1285. doi:10.1093/infdis/jit317.
110. Minas K, Liversidge J (2006) Is the CD200/CD200. receptor interaction more than just a myeloid cell inhibitory signal? Crit Rev Immunol 26:213–230.
111. Moncla BJ, Braham P (1989) Detection of sialidase (neuraminidase) activity in Actinomyces species by using 2’-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid in a filter paper spot test. J Clin Microbiol 27:182–184.
112. Moncla BJ, Braham P, Hillier SL (1990) Sialidase (neuraminidase) activity among gram-negative anaerobic and capnophilic bacteria. J Clin Microbiol 28:422–425.
113. Montgomery CP, Boyle-Vavra S, Adem PV et al (2008) Comparison of virulence in communityassociated methicillin-resistant Staphylococcus aureus pulsotypes USA300. and USA400. in a rat model of pneumonia. J Infect Dis 198:561–570. doi:10.1086/590157.
114. Morens DM, Taubenberger JK, Fauci AS (2008) Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 198:962–970. doi:10.1086/591708.
115. Moscona A (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353:1363–1373. doi:10.1056/NEJMra050740.
116. Murphy TF, Bakaletz LO, Smeesters PR (2009) Microbial interactions in the respiratory tract. Pediatr Infect Dis J 28:S121–S126. doi:10.1097/INF.0b013e3181b6d7ec
117. Musher DM, Dowell ME, Shortridge VD et al (2002) Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 346:630–631. doi:10.1056/ NEJM200202213460820.
118. Nakamura S, Davis KM, Weiser JN (2011) Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Invest 121:3657–3665. doi:10.1172/JCI57762.
119. Navarini AA, Recher M, Lang KS et al (2006) Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. Proc Nat Acad Sci U.S.A 103:15535–15539. doi:10.1073/pnas.0607325103.
120. Nelson JC, Jackson M, Yu O et al (2008) Impact of the introduction of pneumococcal conjugate vaccine on rates of communityacquired pneumonia in children and adults. Vaccine 26:4947–4954. doi:10.1016/j.vaccine.2008.07.016.
121. Niemann S, Ehrhardt C, Medina E et al (2012) Combined action of influenza virus and Staphylococcus aureus panton-valentine leukocidin provokes severe lung epithelium damage. J Infect Dis 206:1138–1148. doi:10.1093/infdis/jis468.
122. Nishikawa T, Shimizu K, Tanaka T et al (2012) Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor. PLoS ONE 7:e45371. doi:10.1371/journal.pone.0045371.
123. Nonaka H, Ishikawa Y, Otsuka M et al (1983) Purification and some properties of neuraminidase isolated from the culture medium of oral bacterium Streptococcus mitis ATCC 9811. J Dent Res 62:792–797.
124. Okamoto S, Kawabata S, Nakagawa I et al (2003) Influenza A virus-infected hosts boost an invasive type of Streptococcus pyogenes infection in mice. J Virol 77:4104–4112.
125. Oseasohn R, Adelson L, Kaji M (1959) Clinicopathologic study of thirty-three fatal cases of Asian influenza. N Engl J Med 260:509–518. doi:10.1056/NEJM195903122601101.
126. Palacios G, Hornig M, Cisterna D et al (2009) Streptococcus pneumoniae coinfection is correlated with the severity of H1N1. pandemic influenza. PLoS ONE 4:e8540. doi:10.1371/journal.pone.0008540.
127. Pawelek KA, Huynh GT, Quinlivan M et al (2012) Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comput Biol 8:e1002588. doi:10.1371/journal.pcbi.1002588.
128. Peltola VT, Boyd KL, McAuley JL et al (2006) Bacterial sinusitis and otitis media following influenza virus infection in ferrets. Infect Immun 74:2562–2567. doi:10.1128/IAI.74.5.2562-2567.2006.
129. Peltola VT, Murti KG, McCullers JA (2005) Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 192:249–257. doi:10.1086/430954.
130. Pettigrew MM, Gent JF, Revai K et al (2008) Microbial interactions during upper respiratory tract infections. Emerg Infect Dis 14:1584–1591. doi:10.3201/eid1410.080119.
131. Pittet LA, Hall-Stoodley L, Rutkowski MR, Harmsen AG (2010) Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae. Am J Respir Cell Mol Biol 42:450–460. doi:10.1165/rcmb.2007-0417OC
132. Plotkowski MC, Bajolet-Laudinat O, Puchelle E (1993) Cellular and molecular mechanisms of bacterial adhesion to respiratory mucosa. Eur Respir J 6:903–916.
133. Plotkowski MC, Puchelle E, Beck G et al (1986) Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8. virus. Am Rev Respir Dis 134:1040–1044.
134. Puchelle E, Zahm J-M, Tournier J-M, Coraux C (2006) Airway epithelial repair, regeneration, and remodeling after injury in chronic obstructive pulmonary disease. Proc Am Thorac Soc 3:726–733. doi:10.1513/pats.200605-126SF
135. Rarey KE, DeLacure MA, Sandridge SA, Small PA (1987) Effect of upper respiratory infection on hearing in the ferret model. Am J Otolaryngol 8:161–170. doi:10.1016/S0196-0709(87)80040-6.
136. Redford PS, Mayer-Barber KD, McNab FW et al (2014) Influenza A virus impairs control of mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. J Infect Dis 209:270–274. doi:10.1093/infdis/jit424.
137. Saenz RA, Quinlivan M, Elton D et al (2010) Dynamics of influenza virus infection and pathology. J Virol 84:3974–3983. doi:10.1128/JVI.02078-09.
138. Scanlon KL, Diven WF, Glew RH (1989) Purification and properties of Streptococcus pneumoniae neuraminidase. Enzyme 41:143–150.
139. Seki M, Yanagihara K, Higashiyama Y et al (2004) Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur Respir J 24:143–149. doi:10.1183/09031936.04.00126103.
140. Shahangian A, Chow EK, Tian X et al (2009) Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 119:1910–1920. doi:10.1172/JCI35412.
141. Shanks GD, Mackenzie A, McLaughlin R et al (2010) Mortality risk factors during the 1918-1919. influenza pandemic in the Australian army. J Infect Dis 201:1880–1889. doi:10.1086/652868.
142. Shope RE (1931) Swine influenza: I. Experimental transmission and pathology. J Exp Med 54:349–359. doi:10.1084/jem.54.3.349.
143. Short KR, Diavatopoulos DA, Thornton R et al (2011) Influenza virus induces bacterial and nonbacterial otitis media. J Infect Dis 204:1857–1865. doi:10.1093/infdis/jir618.
144. Short KR, Habets MN, Hermans PW, Diavatopoulos DA (2012a) Interactions between Streptococcus pneumoniae and influenza virus: a mutually beneficial relationship? Future Microbiol 7:609–624. doi:10.2217/fmb.12.29.
145. Short KR, Habets MN, Payne J et al (2013a) Influenza A virusinduced bacterial otitis media is independent of virus tropism for a2,6-linked sialic acid. Virol J 10:128. doi:10.1186/1743-422X-10-128.
146. Short KR, Reading PC, Brown LE et al (2013b) Influenza-induced inflammation drives pneumococcal otitis media. Infect Immun 81:645–652. doi:10.1128/IAI.01278-12.
147. Short KR, Reading PC, Wang N et al (2012b) Increased nasopharyngeal bacterial titers and local inflammation facilitate transmission of Streptococcus pneumoniae. mBio 3:e00255–12. doi:10.1128/mBio.00255-12.
148. van der Sluijs KF, van Elden LJR, Nijhuis M et al (2004) IL-10. is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol (Baltimore Md 1950) 172:7603–7609.
149. Small C-L, Shaler CR, McCormick S et al (2010) Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J Immunol 184:2048–2056. doi:10.4049/jimmunol.0902772.
150. Smith AM, Adler FR, McAuley JL et al (2011a) Effect of 1918. PB1-F2. expression on influenza A virus infection kinetics. PLoS Comput Biol 7:e1001081. doi:10.1371/journal.pcbi.1001081.
151. Smith AM, Adler FR, Perelson AS (2010) An accurate two-phase approximate solution to an acute viral infection model. J Math Biol 60:711–726. doi:10.1007/s00285-009-0281-8.
152. Smith AM, Adler FR, Ribeiro RM et al (2013) Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog 9:e1003238. doi:10.1371/journal.ppat.1003238.
153. Smith AM, McCullers JA (2013) Molecular signatures of virulence in the PB1-F2. proteins of H5N1. influenza viruses. Virus Res 178:146–150. doi:10.1016/j.virusres.2013.02.012.
154. Smith AM, McCullers JA, Adler FR (2011b) Mathematical model of a three-stage innate immune response to a pneumococcal lung infection. J Theor Biol 276:106–116. doi:10.1016/j.jtbi.2011.01.052.
155. Smith AM, Perelson AS (2011) Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip Rev Syst Biol Med 3:429–445. doi:10.1002/wsbm.129.
156. Smith AM, Ribeiro RM (2010) Modeling the viral dynamics of influenza A virus infection. Crit Rev Immunol 30:291–298. doi:10.1615/CritRevImmunol.v30.i3.60.
157. Smith MW, Schmidt JE, Rehg JE et al (2007) Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza. Comp Med 57:82–89.
158. Snelgrove RJ, Goulding J, Didierlaurent AM et al (2008) A critical function for CD200. in lung immune homeostasis and the severity of influenza infection. Nat Immunol 9:1074–1083. doi:10.1038/ni.1637.
159. Sun K, Metzger DW (2008) Inhibition of pulmonary antibacterial defense by interferon-c during recovery from influenza infection. Nat Med 14:558–564. doi:10.1038/nm1765.
160. Tashiro M, Ciborowski P, Klenk H-D et al (1987) Role of Staphylococcus protease in the development of influenza pneumonia. Nature 325:536–537. doi:10.1038/325536a0.
161. Tian X, Xu F, Lung WY et al (2012) Poly I: C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria. PLoS ONE 7:e41879. doi:10.1371/journal.pone.0041879.
162. Tong HH, Weiser JN, James MA, DeMaria TF (2001) Effect of influenza A virus infection on nasopharyngeal colonization and otitis media induced by transparent or opaque phenotype variants of Streptococcus pneumoniae in the chinchilla model. Infect Immun 69:602–606. doi:10.1128/IAI.69.1.602-606.2001.
163. Tuomanen EI, Austrian R, Masure HR (1995) Pathogenesis of pneumococcal infection. N Engl J Med 332:1280–1284. doi:10.1056/NEJM199505113321907.
164. Varga ZT, Grant A, Manicassamy B, Palese P (2012) Influenza virus protein PB1-F2. inhibits the induction of type I interferon by binding to MAVS and decreasing mitochondrial membrane potential. J Virol 86:8359–8366. doi:10.1128/JVI.01122-12.
165. Varga ZT, Ramos I, Hai R et al (2011) The influenza virus protein PB1-F2. inhibits the induction of type I interferon at the level of the MAVS adaptor protein. PLoS Pathog 7:e1002067. doi:10.1371/journal.ppat.1002067.
166. Wang J, Li F, Sun R et al (2013) Bacterial colonization dampens influenza-mediated acute lung injury via induction of M2. alveolar macrophages. Nat Commun. doi:10.1038/ncomms3106.
167. Wanzeck K, Boyd KL, McCullers JA (2011) Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice. Am J Respir Crit Care Med 183:767–773. doi:10.1164/rccm.201007-1184OC
168. Weeks-Gorospe JN, Hurtig HR, Iverson AR et al (2012) Naturally occurring swine influenza A virus PB1-F2. phenotypes that contribute to superinfection with gram-positive respiratory pathogens. J Virol 86:9035–9043. doi:10.1128/JVI.00369-12.
169. Weinberger DM, Simonsen L, Jordan R et al (2011) Impact of the 2009. influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis 205:458–465. doi:10.1093/infdis/jir749.
170. Wherry WB, Butterfield CT (1921) Inhalation experiments on influenza and pneumonia, and on the importance of spray-borne bacteria in respiratory infections. Public Health Rep (1896–1970) 36:1443. doi:10.2307/4576030.
171. World Health Organization Global Burden of Disease
172. World Health Organization Writing Group, Bell D, Nicoll A et al (2006) Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis 12:81–87. doi:10.3201/eid1201.051370.
173. Wu Y, Mao H, Ling M-T et al (2011) Successive influenza virus infection and Streptococcus pneumoniae stimulation alter human dendritic cell function. BMC Infect Dis 11:201. doi:10.1186/1471-2334-11-201.
174. Zamarin D, García-Sastre A, Xiao X et al (2005) Influenza virus PB1-F2. protein induces cell death through mitochondrial ANT3. and VDAC1. PLoS Pathog 1:e4. doi:10.1371/journal.ppat.0010004.
175. Zamarin D, Ortigoza MB, Palese P (2006) Influenza A virus PB1-F2. protein contributes to viral pathogenesis in mice. J Virol 80:7976–7983. doi:10.1128/JVI.00415-06.
176. Zell R, Krumbholz A, Eitner A et al (2007) Prevalence of PB1-F2. of influenza A viruses. J Gen Virol 88:536–546. doi:10.1099/vir.0.82378-0